Investigational New Drugs

, Volume 26, Issue 1, pp 1–5 | Cite as

INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin

  • Kathryn A. MasonEmail author
  • David Valdecanas
  • Nancy R. Hunter
  • Luka Milas


Poly(ADP-ribose) synthetase inhibitor, INO-1001, is known to sensitize cells to radiation in vitro by inhibiting the repair of DNA damage. Recent evidence has suggested that PARP inhibition may also be a way of selectively targeting p53 deficient cancer cells. The present study tested INO-1001 for its in vivo effect on the chemoresponse of two p53 deficient tumors, human breast cancer MDA-MB-231 and murine mammary carcinoma MCa-K. Doxorubicin was used as the DNA damaging agent and tumor growth delay assay was used as the endpoint. Results showed that INO-1001 was highly effective in enhancing the anti-tumor effects of Doxorubicin for both MDA-MB-231 (EF = 1.88) and MCa-K (EF = 1.64). We conclude that PARP inhibitor INO-1001 has high potential for enhancing the anti-tumor effects of chemotherapy agents such as Doxorubicin against p53 deficient breast cancer.


Poly(ADP-ribose) INO-1001 Doxorubicin p53-Deficient cancer cells Doxorubicin-induced apoptosis 



Sponsored by a Laboratory Study Agreement with Inotek Pharmaceuticals Corp and NIH Grants CA06294 and CA16672.


  1. 1.
    Althaus FR (1985) ADP-Ribosylation of Proteins. Springer, BerlinGoogle Scholar
  2. 2.
    Southan GJ, Szabo C (2003) Poly(ADP-ribose) polymerase inhibitors. Curr Med Chem 10(4):321–340PubMedGoogle Scholar
  3. 3.
    Beneke S, Diefenbach J, Burkle A (2004) Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions. Int J Cancer 111(6):813–818PubMedCrossRefGoogle Scholar
  4. 4.
    Lunee J, George M, Hedges M, Cramp W, Wish W, Hunt B (1984) Post-irradiation sensitization with the ADP-ribosyltransferase inhibitor 3-acetamidobenzamide. Br J Cancer 49:19–25Google Scholar
  5. 5.
    Brown D, Evans J, Brown J (1984) The influence of inhibitors of poly(ADP)polymerase on X-ray induced potentially lethal damage repair. Br J Cancer 49:27–34Google Scholar
  6. 6.
    Ben-Hur B, Utsumi H, Elkind M (1984) Inhibitors of poly(ADP-ribose) synthesis enhance X-ray killing of log phase Chinese hamster cells. Radiat Res 97:546–555PubMedCrossRefGoogle Scholar
  7. 7.
    Ben-Hur E (1984) Involvement of poly (ADP-ribose) in the radiation response of mammalian cells. Int J Radiat Biol 46(6):659–671CrossRefGoogle Scholar
  8. 8.
    Ueno AM, Tanaka O, Matsudaira H (1984) Inhibition of gamma-ray dose-rate effects by D2O and inhibitors of poly(ADP-ribose) synthetase in cultured mammalian L5178Y cells. Radiat Res 98(3):574–582PubMedCrossRefGoogle Scholar
  9. 9.
    Thraves P, Mossman KL, Brennan T, Dritschilo A (1985) Radiosensitization of human fibroblasts by 3-aminobenzamide: An inhibitor of poly(ADP-ribosylation). Radiat Res 104(2 Pt 1):119–127PubMedCrossRefGoogle Scholar
  10. 10.
    Kelland LR, Burgess L, Steel GG (1987) Radiation damage repair capacity of a human germ-cell tumour cell line: inhibition by 3-aminobenzamide. Int J Radiat Biol Relat Stud Phys Chem Med 51(2):227–241PubMedCrossRefGoogle Scholar
  11. 11.
    Arundel-Suto CM, Scavone SV, Turner WR, Suto MJ, Sebolt-Leopold JS (1991) Effect of PD 128763, a new potent inhibitor of poly(ADP-ribose) polymerase, on X-ray-induced cellular recovery processes in Chinese hamster V79 cells. Radiat Res 126(3):367–371PubMedCrossRefGoogle Scholar
  12. 12.
    Brock WA, Milas L, Bergh S, Lo R, Szabo C, Mason KA (2004) Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett 205(2):155–160PubMedCrossRefGoogle Scholar
  13. 13.
    Bowman KJ, White A, Golding B, Griffin R, Curtin N (1998) Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br J Cancer 78(10):1269–1277PubMedGoogle Scholar
  14. 14.
    Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin N, Durkacz B, Hostomsky Z, Newell D (2000) Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 6(7):2860–2867PubMedGoogle Scholar
  15. 15.
    Skalitzky D, Marakovits J, Maegley K, Ekker A, Yu X, Hostomsky Z, Webber S, Eastman B, Almassy R, Li J, Curtin N, Newell D, Calvert A, Griffin R, Golding B (2003) Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem 46(2):210–213PubMedCrossRefGoogle Scholar
  16. 16.
    Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford IJ, Skalitzky D, Thomas HD, Wang LZ, Webber SE, Williams KJ, Curtin NJ (2004) Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 96(1):56–67PubMedCrossRefGoogle Scholar
  17. 17.
    Munoz-Gamez JA, Martin-Oliva D, Aguilar-Quesada R, Canuelo A, Nunez MI, Valenzuela MT, Ruiz de Almodovar JM, De Murcia G, Oliver FJ (2005) PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis. Biochem J 386(Pt 1):119–125PubMedGoogle Scholar
  18. 18.
    Madhusudan S, Middleton M (2005) The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat Rev 31(8):603–617PubMedCrossRefGoogle Scholar
  19. 19.
    Xiao CY, Chen M, Zsengeller Z, Szabo C (2004) Poly (ADP-ribose) polymerase contributes to the development of myocardial infarction in diabetic rats and regulates the nuclear translation of apoptosis-inducing factor. J Pharmacol Exp Ther 310 (2):498–504PubMedCrossRefGoogle Scholar
  20. 20.
    Xiao CY, Chen M, Zsengeller Z, Li H, Kiss L, Kollai M, Szabo C (2005) Poly (ADP-Ribose) polymerase promotes cardiac remodeling, contractile failure, and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure. J Pharmacol Exp Ther 312(3):891–898PubMedCrossRefGoogle Scholar
  21. 21.
    Oren M (2003) Decision making by p53: life, death and cancer. Cell Death Differ 10(4):431–442PubMedCrossRefGoogle Scholar
  22. 22.
    Vogelstein B, Lane D, Levine A (2000) Surfing the p53 network. Nature 408(6810):307–310PubMedCrossRefGoogle Scholar
  23. 23.
    Wahl GM, Carr AM (2001) The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat Cell Biol 3(12):E277–286PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Kathryn A. Mason
    • 1
    Email author
  • David Valdecanas
    • 1
  • Nancy R. Hunter
    • 1
  • Luka Milas
    • 1
  1. 1.Department of Experimental Radiation OncologyThe University of Texas M. D. Anderson Cancer CenterHoustonUSA

Personalised recommendations